Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Immunotherapy, Finally time for T Cells?

This article was originally published in Start Up

Executive Summary

Immunotherapy has seen its share of failures in recent months, but T-cell oriented therapies are by no means dead in the water and therapeutic cancer vaccines continue to attract funding. This month START-UP profiles three companies that nevertheless have been able to attract funding . They aim to avoid the difficulties that have sunk other efforts to commercialize immunotherapies. The firms are transplanting T cells along with same-donor bone marrow to fight infection, delivering powerful cytokines and other therapeutic payloads via T-cell receptor targeting, and genetically enhancing the ability of T-cell receptors to recognize antigens before growing those T cells in culture and re-infusing them into a patient's body.
Advertisement

Related Content

GSK's Early Link-Up with Abbott for an Immunotherapy Companion Diagnostic
Cell Medica Ltd.
Adaptimmune Ltd.
Altor BioScience Corp.
Start-Up Previews (11/2008)
For GlobeImmune, Early HCV Vaccine Data May Spark Coveted Partnership
Cell Genesys/Takeda: Not Quite Validation for Cell Therapy
Amping Up Dendritic Cells
A New Perspective on Cancer Immunotherapy
The Provenge Precedent

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC091506

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel